Next Phase Newsletter

A venture capital firm based in Western Europe invests focuses on investments in technology-based early stage companies in life science industry among other technologically oriented industries. The venture capitalist provides initial investments of up to €600,000-1 million. The firm will also reserve a further €3 million for follow-on financing and supports the start-ups in acquiring other investors and partners. The firm is interested in companies that have been in operation for less than one year. The firm typically looks to make 10-15 life science investments per year. The firm invests primarily in Germany but also has the capacity to invest in other parts of Europe or in global companies that have ties to Germany. The firm only invests in companies that are less than 3 years old.

The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices, material sciences, chemicals, regenerative energies and healthcare IT sectors. The firm is opportunistic in terms of sector, subsectors and indications, but it focuses on companies with a significant technological innovation and close to proof of concept. The firm’s investments to date have included life science companies developing medical devices, vaccines, drugs development, diagnostic services, chemicals and platform technologies.

The firm mostly invests in seed-stage companies located in Germany (or at least have a German subsidiary) with deep technological knowledge and expertise. The target market should be large and/or have high growth potential. The founding team should have the relevant know-how, complimentary skills and relevant business / industry experience. Outside of Germany, the firm only invests as a co-investor alongside a local lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices throughout Western Europe has raised 6 funds to date, and allocates up to €10M in equity per company. The firm’s investment focus is on fast growing high-tech companies in global technology markets such as telecommunications and IT, internet/media, nanotechnology, new materials, electronics, cleantech and life science. The firm invests in companies that are based in Europe. The firm is actively seeking new investments.

In the Life Sciences, the firm seeks to invest in early-stage therapeutic discovery/technology platform, R&D services, and medical device companies. For medical devices, the firm prefers products that are close to market commercialization. The firm is opportunistic in terms of subsectors and indications. Historically, the firm invested in proteomics, CRO, cell-based expression systems, small molecule drug discovery, cell modeling/viral vector platforms, cancer diagnostics, and drug delivery. The firm does not invest in drug development.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A privately-owned designer, developer and manufacturer of advanced drug delivery systems who is active in R&D, design and manufacturing in all areas of healthcare, is actively seeking partnering opportunities with early-stage companies. The firm is capable of a variety of deal structures, but prefers to enter into joint ventures and strategic partnerships as the firm seeks to be a value-added investor providing their expertise and capabilities in design and manufacturing as well as the resources of a large company while allowing the entrepreneur to drive the development of the technology.

The firm’s expertise lies in drug delivery devices, but has capabilities and is highly interested in all areas of medical technology/devices, biosensors and wearables, B2B or B2C healthcare IT applications including data analytics and cloud computing as well as robotics and AI as it applies to surgery prosthetics, rehabilitation and drug discovery. The firm has a particular interest in the diabetes space and has done work in this area in the past.

The firm is open to working with all entrepreneurs and is open to companies on a global basis. The firm does look for a board seat along with an investment, but strives to not be restrictive in any way and let the management team run the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A China-based healthcare fund focuses on global growth opportunities. The firm is based in Shanghai with several offices in the USA. In addition, the firm launched a sister fund that is focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through the firm is US $5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China, Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, digital health and healthcare services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage. In the Diagnostics space, the firm only looks for products in the commercial stage from China.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A group of globally acting venture capital and private equity firms with an operating track record that span decades, operate globally with dedicated Life Science venture capital funds with a global footprint. The group’s Life Science Venture arm is looking to provide seed, venture and growth capital to companies in the life science space. The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investments located globally.

The firm is a dedicated provider of venture capital to the international pharmaceutical, medical technology and healthcare diagnostics industries, hence looking to invest in companies in sectors of Medical devices, Diagnostic Tools and Platforms, and Specialty Pharmaceuticals that are later stage with strong in human data (Phase IIb and III or on the market) and have very little regulatory risk. The firm’s most recent Life Science Venture Capital Fund focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise. The firm is also less inclined to invest into orphan indication.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA fund seeks to in-license 4-6 IND-ready assets and develop them through Phase 2b. After proof-of-concept is established, the firm will seek to exit. Roughly 90% of the fund will be used to fund development, with clinical trials carried out by the firm. They are particularly interested in therapeutics falling in the sectors of neuroscience and immunology.

The firm is seeking small molecules and biologics in the areas of neuroscience and immunology that can improve patient lives. The firm does not consider drugs for highly crowded spaces, for example oncology or disease-modifying drugs for Alzheimer’s. Levadopa-induced dyskinesia in Parkinson’s and ataxia have been areas of interest, and they will consider therapeutics for orphan and rare diseases. Drug platforms addressing self-similar indications/targets are also of interest.

The firm looks for IND-ready drugs that can be developed or re-purposed, and will conduct a thorough due diligence taking 6 months to a year. The opportunity should have a clear regulatory and development pathway and good prospects for an exit within 4 years of acquisition. With strong scientific backgrounds themselves, the firm respects the expertise of the innovators. The firm will work with founders to arrange a deal, and are open to negotiating option agreements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in the USA invests in seed and early-stage digital health and therapeutic companies. The typical investment size for seed investment ranges from $500K to $1M (usually in equity or capped, convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based in the United States. The firm is actively seeking new investment opportunities.

The firm is actively seeking new investment opportunities in the digital health sector and areas of interest include: Precision medicine, digital therapeutics, combination data products, scalability solutions and clinical trial management solutions.

The firm often leads financings and takes a board seats. They prefer to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.